A_2B adenosine receptor antagonists and their potential indications

Bibliography

• FOZARD JR, MCCARTH C: Adenosine receptor ligands as potential therapeutics in asthma. Curr. Opin. Investig. Drugs (2002) 3(1):69-77.
   PubMedGoogle Scholar
• JACOBSON KA, GAO Z-G: Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discov. (2006) 5(3):247-264.
   PubMed Web of Science ®Google Scholar
• FEOKTISTOV I, WELLS JN, BIAGGIONI I: Adenosine A2B receptors as therapeutic targets. Drug Dev. Res. (1998) 45(3/4):198-206.
   Web of Science ®Google Scholar
• VOLPINI R, COSTANZI S, VITTORI S, CRISTALLI G, KOLTZ K-N: Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr. Top. Med. Chem. (2003) 3:427-443.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST: The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br. J. Pharmacol. (2005) 145(8):1009-1015.
   PubMed Web of Science ®Google Scholar
• KURUKULASURIYA R, LINK JT, MADAR DJ et al.: Potential drug targets and progress towards pharmacologic inhibition of hepatic glucose production. Curr. Med. Chem. (2003) 10(2):123-153.
   PubMed Web of Science ®Google Scholar
• HAYALLAH AM, SANDOVAL-RAMIREZ J, REITH U et al.: 1,8-Disubstituted xanthine derivatives: synthesis of potent A2B -selective adenosine receptor antagonists. J. Med. Chem. (2002) 45(7):1500-1510.
   PubMed Web of Science ®Google Scholar
• HARADA H, ASANO O, KAWATA T et al.: 2-Alkynyl-8-aryladenines possessing an amide moiety: their synthesis and structure-activity relationships of effects on hepatic glucose production induced via agonism of the A2B adenosine receptor. Bioorg. Med. Chem. Lett. (2001) 9(10):2709-2726.
   Google Scholar
• GRANT MB, TARNUZZER RW, CABALLERO S et al.: Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ. Res. (1999) 85:699-706.
   PubMed Web of Science ®Google Scholar
• FEOKTISTOV I, RYZHOV S, ZHONG H et al.: Hypoxia modulates adenosine receptors in human endothelial and smooth muscle cells toward an A2B angiogenic phenotype. Hypertension (2004) 44(5):649-654.
   PubMed Web of Science ®Google Scholar
• ABO-SALEM OM, HAYALLAH AM, BILKEI-GORZO A et al.: Antinociceptive effects of novel A2B adenosine receptor antagonists. J. Pharmacol. Exp. Ther. (2004) 308(1):358-366.
   PubMed Web of Science ®Google Scholar
• ZHONG H, BELARDINELLI L, MAA T et al.: A2B adenosine receptors increase cytokine release by bronchial smooth muscle cells. Am. J. Respir. Cell Mol. Biol. (2004) 30(1):118-125.
   PubMed Web of Science ®Google Scholar
• RYZHOV S, GOLDSTEIN AE, MATAFONOV A et al.: Adenosine-activated mast cells induce IgE synthesis by B Lymphocytes: An A2B-mediated process involving TH2 Cytokines IL-4 and IL-13 with implications for asthma. J. Immunol. (2004) 172:7726-7733.
   PubMed Web of Science ®Google Scholar
• D'ALONZO GE: Theophylline revisited. Allergy. Asthma. Proc. (1996) 17:335-339.
   PubMed Web of Science ®Google Scholar
• POWELL EC, REYNOLDS SL, RUBENSTEIN JS: Theophylline toxicity in children: a retrospective review. Pediatr. Emerg. Care. (1993) 9:129-133.
   PubMed Web of Science ®Google Scholar
• JACOBSON KA, IJZERMAN AP, LINDEN J: 1,3-Dialkylxanthie derivatives having high potency as antagonists at human A2B adenosine receptors. Drug Dev. Res. (1999) 47:45-53.
   Web of Science ®Google Scholar
• KIM Y-C, JI X-D, MELMAN N et al.: Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J. Med. Chem. (2000) 43(6):1165-1172.
   PubMed Web of Science ®Google Scholar
• ZABLOCKI J, KALLA R, PERRY T et al.: The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma. Bioorg. Med. Chem. Lett. (2005) 15(3):609-612.
   PubMed Web of Science ®Google Scholar
• ELZEIN E, KALLA R, LI X et al.: Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists. Bioorg. Med. Chem. Lett. (2006) 16(2):302-306.
   PubMed Web of Science ®Google Scholar
• KALLA RV, ELZEIN E, PERRY T et al.: Novel 1,3- disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists. J. Med. Chem. (2006) 49(12):3682-3692.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, TABRIZI MA, PRETI D et al.: Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J. Med. Chem. (2004) 47(6):1434-1447.
   PubMed Web of Science ®Google Scholar
• CAROTTI A, STEFANACHI A, RAVINA E et al.: 8-Substituted-9-deazaxanthines as adenosine receptor ligands: design, synthesis and structure–affinity relationships at A2B. European J. Med. Chem. (2004) 39(10):879-887.
   PubMed Web of Science ®Google Scholar
• CAROTTI A, CADAVID MI, CENTENO NB et al.: Design, synthesis, and structure–activity relationships of 1-, 3-, 8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor. J. Med. Chem. (2006) 49(1):282-299.
   PubMed Web of Science ®Google Scholar
• STEWART M, STEINIG AG, MA C, SONG J, MCKIBBEN B, CASTELHANO AL: [3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem. Pharmacol. (2004) 68(2):305-312.
   PubMed Web of Science ®Google Scholar
• TRIFILIEFF A, KELLER TH, PRESS NJ et al.: CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br. J. Pharmacol. (2005) 144(7):1002-1010.
   PubMed Web of Science ®Google Scholar
• PRESS NJ, TAYLOR RJ, FULLERTON JD et al.: A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential. Bioorg. Med. Chem. Lett. (2005) 15(12):3081-3085.
   PubMed Web of Science ®Google Scholar
• HARADA H, ASANO O, HOSHINO Y et al.: 2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure–activity relationships toward hepatic glucose production induced via agonism of the A2B receptor. J. Med. Chem. (2001) 44(2):170-179.
   PubMed Web of Science ®Google Scholar